NCT00635726 - Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Bladder Cancer

Interventions

DRUG

Methotrexate

Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses

DRUG

Vinblastine

Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses

DRUG

Doxorubicin

Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses

DRUG

Cisplatin

Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses

DRUG

Cisplatin

Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses

DRUG

Gemcitabine

Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses

Trial Locations (7)

University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupoli

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dept. of Medical Oncology, Athens

IASO General Hospital of Athens, 1st Dept. of Medical Oncology, Athens

Laikon General Hospital, Medical Oncology Unit, Propedeutic Dept. of Internal Medicine, Athens

Metaxa's Anticancer Hospital of Piraeus, 1st Dept. of Medical Oncology, Piraeus

Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki